Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets

Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine resulting in the formation of recurring cystine kidney stones. THIOLA EC is expected to be available in July 2019…

READ FULL STORY HERE

Share this post